IRCT20200105046010N30招募中未知
In- Vivo Bioequivalence study of Favipiravir tablet 200mg ABIDI with brand drugs (AVIGAN 200mg, Tayoma Chemical Co. Ind. Japan) in Iranian healthy volunteers.
ABIDI Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
已完成
不适用
The Real-world Clinical Outcomes of Favipiravir Treatment in Mild to Moderate COVID-19 Patients in Single Outpatient Visit Followed by Home Isolation: a Multicenter, case-control StudyTCTR20221113004Chulabhorn Royal Academy1,037
已完成
不适用
Investigation on the effect of favipiravir in preventing Ebola virus disease and its safetyEbola virus diseaseJPRN-UMIN000016102ational Center for Global Health and Medicine25
招募中
3 期
The therapeutic effect of Favipiravir in COVID-19 patientsIRCT20211004052664N1Shahid Beheshti University of Medical Sciences80
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
招募中
不适用
In-vivo Bioequivalence Test of Tenofovir Alafenamide tablets with brand drug (Vemlidy® 25 mg, Gilead, Canada)Bio equivalence test.IRCT20200105046010N52Sobhan Trade Pharmaceutical Company24